Brief: IntelGenx Says Study Results Demonstrated Rizaort Is Bioequivalent To U.S. Reference, Maxalt-MTL
24/09/2018 13:34
Sept 24 (Reuters) - Intelgenx Technologies Corp IGX.V :
* INTELGENX ANNOUNCES SUCCESSFUL RESULTS FROM RIZAPORT®
BIOEQUIVALENCE STUDY
* INTELGENX TECHNOLOGIES - STUDY RESULTS DEMONSTRATED
RIZAORT IS
BIOEQUIVALENT TO U.S. REFERENCE, MAXALT-MTL, AND EUROPEAN
REFERENCE, MAXALT-LINGUA
Source text for Eikon: ID:nGNX405gDx
Further company coverage: IGX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA